Autologous stem cell transplantation for Hodgkin's disease: Busulfan, melphalan and thiotepa compared to a radiaton-based regimen

F. Gutierrez-Delgado, L. Holmberg, H. Hooper, S. Petersdorf, O. Press, Richard Maziarz, D. Maloney, T. Chauncey, F. Appelbaum, W. Bensinger

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We evaluated prognostic factors and treatment outcome of patients with relapsed/refractory Hodgkin's disease (HD) receiving autologous stem cell transplantation (ASCT). In total, 92 patients received total body irradiation, cyclophosphamide and etoposide (TBI/CY/ E) (n = 42) or busulfan, melphalan and thiotepa (Bu/Mel/ T) (n = 50) supported with ASCT. A total of 33 (66%) patients receiving the Bu/Mel/T regimen had a prior history of dose-limiting irradiation. Mucositis, hepatic and pulmonary toxicities were the main causes of morbidity and mortality, irrespective of the conditioning regimen. The transplant-related mortality was 15%. With a median follow-up of 6 years (range 2.5-11), the cumulative probabilities of survival, event-free survival (EFS) and relapse at 6 years were 55, 51 and 32%. The 6-year Kaplan-Meier (KM) probabilities of EFS for patients with less advanced disease (patients in first chemotherapy-responsive relapse or second remission (n = 42)) and more advanced disease (all other patients (n = 50)) were 60 and 44%. No differences in toxicities and efficacy between the conditioning regimens were found. ASCT is an effective treatment for patients with refractory/relapsed HD. Female patients and patients with less advanced disease at transplant had a better outcome. Patients with prior irradiation benefited from the Bu/Mel/T regimen.

Original languageEnglish (US)
Pages (from-to)279-285
Number of pages7
JournalBone Marrow Transplantation
Volume32
Issue number3
DOIs
StatePublished - Aug 2003
Externally publishedYes

Fingerprint

Thiotepa
Busulfan
Melphalan
Stem Cell Transplantation
Hodgkin Disease
Disease-Free Survival
Transplants
Recurrence
Mucositis
Mortality
Whole-Body Irradiation
Etoposide
Cyclophosphamide

Keywords

  • Autologous
  • High dose chemotherapy
  • Hodgkin's disease
  • Stemcell transplant
  • Total body irradiation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous stem cell transplantation for Hodgkin's disease : Busulfan, melphalan and thiotepa compared to a radiaton-based regimen. / Gutierrez-Delgado, F.; Holmberg, L.; Hooper, H.; Petersdorf, S.; Press, O.; Maziarz, Richard; Maloney, D.; Chauncey, T.; Appelbaum, F.; Bensinger, W.

In: Bone Marrow Transplantation, Vol. 32, No. 3, 08.2003, p. 279-285.

Research output: Contribution to journalArticle

Gutierrez-Delgado, F, Holmberg, L, Hooper, H, Petersdorf, S, Press, O, Maziarz, R, Maloney, D, Chauncey, T, Appelbaum, F & Bensinger, W 2003, 'Autologous stem cell transplantation for Hodgkin's disease: Busulfan, melphalan and thiotepa compared to a radiaton-based regimen', Bone Marrow Transplantation, vol. 32, no. 3, pp. 279-285. https://doi.org/10.1038/sj.bmt.1704110
Gutierrez-Delgado, F. ; Holmberg, L. ; Hooper, H. ; Petersdorf, S. ; Press, O. ; Maziarz, Richard ; Maloney, D. ; Chauncey, T. ; Appelbaum, F. ; Bensinger, W. / Autologous stem cell transplantation for Hodgkin's disease : Busulfan, melphalan and thiotepa compared to a radiaton-based regimen. In: Bone Marrow Transplantation. 2003 ; Vol. 32, No. 3. pp. 279-285.
@article{ffff33d0f590434cae37fdf8e98c155c,
title = "Autologous stem cell transplantation for Hodgkin's disease: Busulfan, melphalan and thiotepa compared to a radiaton-based regimen",
abstract = "We evaluated prognostic factors and treatment outcome of patients with relapsed/refractory Hodgkin's disease (HD) receiving autologous stem cell transplantation (ASCT). In total, 92 patients received total body irradiation, cyclophosphamide and etoposide (TBI/CY/ E) (n = 42) or busulfan, melphalan and thiotepa (Bu/Mel/ T) (n = 50) supported with ASCT. A total of 33 (66{\%}) patients receiving the Bu/Mel/T regimen had a prior history of dose-limiting irradiation. Mucositis, hepatic and pulmonary toxicities were the main causes of morbidity and mortality, irrespective of the conditioning regimen. The transplant-related mortality was 15{\%}. With a median follow-up of 6 years (range 2.5-11), the cumulative probabilities of survival, event-free survival (EFS) and relapse at 6 years were 55, 51 and 32{\%}. The 6-year Kaplan-Meier (KM) probabilities of EFS for patients with less advanced disease (patients in first chemotherapy-responsive relapse or second remission (n = 42)) and more advanced disease (all other patients (n = 50)) were 60 and 44{\%}. No differences in toxicities and efficacy between the conditioning regimens were found. ASCT is an effective treatment for patients with refractory/relapsed HD. Female patients and patients with less advanced disease at transplant had a better outcome. Patients with prior irradiation benefited from the Bu/Mel/T regimen.",
keywords = "Autologous, High dose chemotherapy, Hodgkin's disease, Stemcell transplant, Total body irradiation",
author = "F. Gutierrez-Delgado and L. Holmberg and H. Hooper and S. Petersdorf and O. Press and Richard Maziarz and D. Maloney and T. Chauncey and F. Appelbaum and W. Bensinger",
year = "2003",
month = "8",
doi = "10.1038/sj.bmt.1704110",
language = "English (US)",
volume = "32",
pages = "279--285",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Autologous stem cell transplantation for Hodgkin's disease

T2 - Busulfan, melphalan and thiotepa compared to a radiaton-based regimen

AU - Gutierrez-Delgado, F.

AU - Holmberg, L.

AU - Hooper, H.

AU - Petersdorf, S.

AU - Press, O.

AU - Maziarz, Richard

AU - Maloney, D.

AU - Chauncey, T.

AU - Appelbaum, F.

AU - Bensinger, W.

PY - 2003/8

Y1 - 2003/8

N2 - We evaluated prognostic factors and treatment outcome of patients with relapsed/refractory Hodgkin's disease (HD) receiving autologous stem cell transplantation (ASCT). In total, 92 patients received total body irradiation, cyclophosphamide and etoposide (TBI/CY/ E) (n = 42) or busulfan, melphalan and thiotepa (Bu/Mel/ T) (n = 50) supported with ASCT. A total of 33 (66%) patients receiving the Bu/Mel/T regimen had a prior history of dose-limiting irradiation. Mucositis, hepatic and pulmonary toxicities were the main causes of morbidity and mortality, irrespective of the conditioning regimen. The transplant-related mortality was 15%. With a median follow-up of 6 years (range 2.5-11), the cumulative probabilities of survival, event-free survival (EFS) and relapse at 6 years were 55, 51 and 32%. The 6-year Kaplan-Meier (KM) probabilities of EFS for patients with less advanced disease (patients in first chemotherapy-responsive relapse or second remission (n = 42)) and more advanced disease (all other patients (n = 50)) were 60 and 44%. No differences in toxicities and efficacy between the conditioning regimens were found. ASCT is an effective treatment for patients with refractory/relapsed HD. Female patients and patients with less advanced disease at transplant had a better outcome. Patients with prior irradiation benefited from the Bu/Mel/T regimen.

AB - We evaluated prognostic factors and treatment outcome of patients with relapsed/refractory Hodgkin's disease (HD) receiving autologous stem cell transplantation (ASCT). In total, 92 patients received total body irradiation, cyclophosphamide and etoposide (TBI/CY/ E) (n = 42) or busulfan, melphalan and thiotepa (Bu/Mel/ T) (n = 50) supported with ASCT. A total of 33 (66%) patients receiving the Bu/Mel/T regimen had a prior history of dose-limiting irradiation. Mucositis, hepatic and pulmonary toxicities were the main causes of morbidity and mortality, irrespective of the conditioning regimen. The transplant-related mortality was 15%. With a median follow-up of 6 years (range 2.5-11), the cumulative probabilities of survival, event-free survival (EFS) and relapse at 6 years were 55, 51 and 32%. The 6-year Kaplan-Meier (KM) probabilities of EFS for patients with less advanced disease (patients in first chemotherapy-responsive relapse or second remission (n = 42)) and more advanced disease (all other patients (n = 50)) were 60 and 44%. No differences in toxicities and efficacy between the conditioning regimens were found. ASCT is an effective treatment for patients with refractory/relapsed HD. Female patients and patients with less advanced disease at transplant had a better outcome. Patients with prior irradiation benefited from the Bu/Mel/T regimen.

KW - Autologous

KW - High dose chemotherapy

KW - Hodgkin's disease

KW - Stemcell transplant

KW - Total body irradiation

UR - http://www.scopus.com/inward/record.url?scp=10744229853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744229853&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704110

DO - 10.1038/sj.bmt.1704110

M3 - Article

C2 - 12858199

AN - SCOPUS:10744229853

VL - 32

SP - 279

EP - 285

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -